Drug Trial Radar · NCT05514340
Assess Safety and Efficacy of Sovateltide in Hypoxic-ischemic Encephalopathy
Last checked: Nov 19, 2026Latest source record: Dec 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Sep 6, 2023
Primary completion
Nov 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Pharmazz, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 24, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Sovateltide (PMZ-1620; IRL-1620) is targeted to be used as a "Treatment for hypoxic-ischemic encephalopathy in neonates," which is a life-threatening condition. Sovateltide augments neuronal progenitor cell differentiation and better mitochondrial morphology and biogenesis to activate a regenerative response in the central nervous system. The only treatment for HIE is therapeutic hypothermia with limited success, and studies indicate that sovateltide may be beneficial in these patients.
Conditions
- Hypoxic-Ischemic Encephalopathy
- Neonatal Asphyxia
- Neonatal Encephalopathy
Interventions
Normal Saline along with standard treatmentDrug
Sovateltide is an endothelin-B receptor agonist. It has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in hypoxic-ischemic encephalopathy patients. In this arm normal saline along with standard treatment will be given for active comparison.
Sovateltide along with standard treatmentDrug
Sovateltide is an endothelin-B receptor agonist. It has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in hypoxic-ischemic encephalopathy patients. In this arm sovateltide along with standard treatment will be given for active comparison.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of patients with death or disability (moderate/severe)Time frame: 24 months
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Father Muller Medical College Hospital
Mangalore, Karnataka, India · Recruiting
Christian Medical College and Hospital
Ludhiana, Punjab, India · Recruiting
Niloufer Hospital
Hyderabad, Telangana, India · Not yet recruiting
GSVM Medical College
Kanpur, Uttar Pradesh, India · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.